Navigation Links
Cumberland Pharmaceuticals Reports 2011 Annual Financial Results
Date:2/29/2012

43Operating income9,849,4876,501,7475,776,635Interest income210,727200,20779,363Interest expense(353,497)(1,423,523)(772,927)Income before income taxes9,706,7175,278,4315,083,071Income tax expense(4,080,204)(2,851,420)(2,024,192)Net income5,626,5132,427,0113,058,879Net loss at subsidiary attributable to noncontrolling interests31,34329,66932,536Net income attributable to common shareholders$
5,657,856$
2,456,680$
3,091,415Earnings per share attributable to common shareholders- Basic$
.28$
.12$
.22- Diluted$
.28$
.12$
.17Weighted-average shares outstanding- Basic20,342,91320,333,93214,199,479- Diluted20,572,13221,058,57718,234,171CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(Unaudited)Years ended December 31, 2011, 2010 and 2009201120102009Cash flows from operating activities:Net income$
5,626,513$
2,427,011$
3,058,879Adjustments to reconcile net income to net cash flows provided byoperating activities:Depreciation and amortization expense1,040,407978,398816,499Deferred tax expense (benefit)1,665,110(332,349)(525,467)Stock-based compensation - nonemployees149,71980,2221,056,401Stock-based compensation – employees629,586688,408606,395Excess tax benefit derived from exercise of stock options(2,355,345)(3,874,966)(3,968,894)Noncash interest expense137,487352,484128,800Net changes in assets and liabilities affecting operating activities:Accounts receivable(1,937,396)1,031,091(3,047,238)Inventory1,909,148(2,860,969)(3,060,097)Prepaid, other current assets and other assets(399,393)1,342,032(721,464)Accounts payable and other accrued liabilities2,296,535201,7256,572,098Other long-term obligations(40,224)313,575(510,942)Net cash provided by operating activities8,722,147346,662404,970Cash flows from investing activities:Additions to property and equipment(257,502)(577,159)(601,802)Additions to trademarks and patents(180,269)(191,483)(110,541)Net cash used in investing activities(437,77
'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... 2015 , ... Carey Danis & Lowe comments on a new ... Virginia federal court. The court document outlined the judge’s plan to consolidate 26 vaginal ... Carey Danis & Lowe is a personal injury law firm with headquarters in St. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Texas have launched a ‘responsive design’ website to inform potential sinus surgery patients ... them. , The website includes information about a wide variety of ENT issues ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pleased to announce it’s own Debby Mann, CPC, RCC, ROCC, Coding Documentation and ... Summit with the Special Recognition Award for her contribution to the RBMA Coding ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand ... “Grand Terrace Health Care Center.” Each year, Medicare ranks care centers around the ... best facility for their needs. Grand Terrace prides itself on quality in each ...
Breaking Medicine News(10 mins):Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2
... of Pennsylvania School of Medicine have created the first ... a mutation known to produce disease in people, an ... in the October issue of Human Molecular Genetics. ... of vision loss in elderly people, affecting more than ...
... Oct. 9 The following was released,today by the ... MR. TENPAS: Good morning. I am Ronald ... Natural Resources Division here at the,Department of Justice. ... administrator for Enforcement and Compliance Assurance., We ...
... wane over time, study finds , , TUESDAY, Oct. 9 ... who,ve lost weight keep it off, new research suggests. ... of the maintenance programs wears off over time, suggesting ... maintain healthier lifestyles. , "We were excited ...
... a potentially novel way to fight colorectal cancer using ... cancer cells, unlike current treatments that bind to the ... cause unwanted side effects. , In laboratory studies ... system proved able to specifically target colon cancer cells, ...
... NEW YORK, Oct. 9 Highlands Acquisition Corp.,(Amex: HIA.U), ... public offering (the "IPO") of 12,000,000 units. Each unit ... which entitles the holder to,purchase one share of common ... $10.00 per unit, generating gross proceeds of $120,000,000 to ...
... age of 12 currently drink alcohol, according to a ... Services Administration. While the majority of people who drink ... in the expression of violence. , By far the ... violent behavior involves alcohol, says Dr. Jeff Kretschmar, a ...
Cached Medicine News:Health News:Model to study age-related macular degeneration could pave way for better treatment 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Maintenance Treatment Helps Kids Keep Weight Off 2Health News:Maintenance Treatment Helps Kids Keep Weight Off 3Health News:Maintenance Treatment Helps Kids Keep Weight Off 4Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 3
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: